AM Investment Strategies’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.04M Hold
4,149
0.2% 50
2026
Q1
$902K Hold
4,149
0.2% 55
2025
Q4
$948K Sell
4,149
-48
-1% -$10.9K 0.2% 55
2025
Q3
$972K Hold
4,197
0.21% 57
2025
Q2
$779K Buy
4,197
+148
+4% +$27.5K 0.18% 61
2025
Q1
$848K Hold
4,049
0.21% 58
2024
Q4
$720K Buy
+4,049
New +$744K 0.18% 62
2024
Q3
Sell
-4,429
Closed -$760K 106
2024
Q2
$760K Sell
4,429
-846
-16% -$140K 0.19% 61
2024
Q1
$961K Buy
5,275
+175
+3% +$30.2K 0.24% 53
2023
Q4
$790K Buy
5,100
+825
+19% +$120K 0.22% 55
2023
Q3
$637K Hold
4,275
0.21% 53
2023
Q2
$576K Buy
4,275
+629
+17% +$92.2K 0.18% 57
2023
Q1
$581K Sell
3,646
-288
-7% -$44K 0.2% 54
2022
Q4
$636K Buy
3,934
+52
+1% +$7.97K 0.23% 51
2022
Q3
$521K Buy
3,882
+448
+13% +$64.3K 0.19% 53
2022
Q2
$526K Sell
3,434
-100
-3% -$15.3K 0.18% 56
2022
Q1
$573K Buy
3,534
+12
+0.3% +$1.74K 0.15% 65
2021
Q4
$477K Sell
3,522
-154
-4% -$18.2K 0.11% 75
2021
Q3
$397K Hold
3,676
0.1% 75
2021
Q2
$414K Hold
3,676
0.11% 74
2021
Q1
$398K Hold
3,676
0.11% 72
2020
Q4
$394K Hold
3,676
0.12% 68
2020
Q3
$322K Buy
+3,676
New +$346K 0.11% 69

Other funds holding ABBV

AM Investment Strategies's ABBV Position: Q2 2026 in Review

AM Investment Strategies held its AbbVie (ABBV) position steady in Q2 2026 at 4,149 shares worth $1.04M. The position accounts for 0.2% of the portfolio, ranked #50.

AM Investment Strategies first reported a position in ABBV in Q3 2020 and has held it in 23 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • AM Investment Strategies held 4,149 shares of AbbVie worth $1.04M as of Q2 2026.
  • AM Investment Strategies left its AbbVie share count unchanged in Q2 2026.
  • AbbVie made up 0.2% of AM Investment Strategies's portfolio in Q2 2026, its #50 holding.
  • AM Investment Strategies first reported a position in AbbVie in Q3 2020 and has held it in 23 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on AM Investment Strategies's 13F filing for Q2 2026, filed 16 Jul 2026.